The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its ...

总之，linvoseltamab的研发成果为难治性癌症患者带来了新的治疗希望，71%的缓解率不禁让我们重新思考癌症治疗的前景与意义。在这一转折点，结合最新药物进展与健康生活方式的整合，将确保患者走出困境，迎接更美好的明天。同时，如果您希望得到针对性的饮食指导，不妨使用搜狐简单AI的健康饮食助手工具，为自己打造个性化的健康方案。 返回搜狐，查看更多 ...

1. 再生元宣布欧洲药品管理局 (EMA)人用药品委员会 (CHMP)采纳积极意见，推荐双特异性抗体疗法linvoseltamab条件性上市，治疗复发/难治性 (R/R)多发性骨髓瘤 (MM)成人患者。

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...

纽约塔里敦 - 市值达752亿美元、年收入142亿美元的生物科技公司Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)获得欧洲药品管理局 (EMA)人用药品委员会 (CHMP)对其候选药物linvoseltamab的积极意见。该药物用于治疗复发和难治性多发性骨髓瘤 (R/R MM)成年患者。根据 InvestingPro ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.